FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says

A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says